WATERTOWN, MA, Seismic Therapeutic, a biotechnology company advancing machine learning for immunology drug development, announced its launch and financing of $101 million.
Seismic Therapeutic, a biotechnology company advancing machine learning for immunology drug development, today announced its launch and financing of $101 million.
The Series A was led by Lightspeed Venture Partners with participation from lead founding investors Timothy A. Springer and Polaris Partners, along with new investors GV, Boxer Capital, Samsara BioCapital, and management and founders.
(c) by Massinvestor, Inc. For contact info, please check out our
about page.
